Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCC dose comparison for reversal of rivaroxaban and apixaban anticoagulation in healthy volunteers
NL-OMON21617Active, not recruiting
- Sponsor
- Academic Medical Center
- Start
- Oct 2012
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of Human prothrombin complex, rivaroxaban and apixaban in anticoagulant reversal (6 arms), sponsored by Academic Medical Center. Primary endpoints: Reversal of coagulation assays and Endogenous thrombin potential. Started Oct 2012; status: active, not recruiting.
02
Drugs
Human prothrombin complexrivaroxabanapixaban
03
Conditions
anticoagulant reversal
Beyond the preview
Go deeper on NL-OMON21617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21617.